Get the Stockscreener App
15.66
2.42%
-0.44
Jade Biosciences Inc stock is traded at $15.66, with a volume of 5,114.
It is down -2.42% in the last 24 hours and down -33.50% over the past month.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
See More
Previous Close:
$16.10
Open:
$15.74
24h Volume:
5,114
Relative Volume:
0.01
Market Cap:
$957.93M
Revenue:
-
Net Income/Loss:
$-129.61M
P/E Ratio:
-5.2425
EPS:
-2.9871
Net Cash Flow:
$-116.59M
1W Performance:
+2.04%
1M Performance:
-33.50%
6M Performance:
-3.18%
1Y Performance:
+122.17%
1-Day Range:
$15.72
$15.74
1-Week Range:
$15.02
$16.60
52-Week Range:
$6.67
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
(781) 312-3013
Address
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
15.74 | 979.84M | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
449.10 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
610.01 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.79 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.64 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.00 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
UBS Initiates Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $45 - Moomoo
UBS Initiates Jade Biosciences at Buy With $45 Price Target - Moomoo
UBS initiates Jade Biosciences stock at Buy on IgAN drug potential - Investing.com Canada
[Form 4] Jade Biosciences, Inc. Insider Trading Activity - Stock Titan
Jade Biosciences (JBIO) director granted 34,843 stock options at $15.22 strike price - Stock Titan
Jade Biosciences (JBIO) awards director 34,843 stock options at $15.22 - Stock Titan
Jade Biosciences (JBIO) director Erin Lavelle receives 34,843-share option grant - Stock Titan
Director Kiselak receives 34,843-share Jade Biosciences (JBIO) stock option grant - Stock Titan
Jade Biosciences (NASDAQ: JBIO) holders back charter and bylaw changes - Stock Titan
Jade Biosciences (JBIO) 10K Form and Latest SEC Filings 2026 - MarketBeat
Jade Biosciences Company Profile & Introduction - Moomoo
Fairmount funds lock up 19.99% stake in Jade Biosciences (JBIO) - Stock Titan
Jade Biosciences' JADE101 delivers deep IgA cuts, clearing path for kidney trials - MSN
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies - Moomoo
Jade Biosciences closes $172.5m public offering - scanx.trade
Jade Biosciences prices $150M public offering of common stock at $15/share - MSN
Jade Biosciences closes $172.5 million stock offering - Investing.com UK
Jade Biosciences closes $172.5 million stock offering By Investing.com - Investing.com South Africa
Jade Biosciences plans public offering, pre-funded warrants - MSN
Jade Biosciences Closes Public Offering of Shares - marketscreener.com
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Press Release: Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - 富途牛牛
Number of shareholders of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Watkins Advises Jade Biosciences on Public Offering of Common Stock - Latham & Watkins LLP
Jade Biosciences Launches Major Underwritten Equity Offering - TipRanks
Jade Bios prices $150M follow-on offering, 10M shares at $15; nets ~$140.3M - TradingView
Jade Biosciences (NASDAQ: JBIO) prices $150M common stock sale - Stock Titan
Jade Biosciences (NASDAQ: JBIO) files prospectus for 10M-share $150M offering - Stock Titan
JADE101 Phase 1 Trial Marks Key Early Milestone for Jade Biosciences Investors - TipRanks
Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE - RTTNews
Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED) - Benzinga
Why is Jade Biosciences stock sliding 9% today? By Investing.com - Investing.com India
Press Release: Jade Biosciences Announces Proposed Underwritten Public Offering - Moomoo
Jade Biosciences Prices $150 Million Public Offering - marketscreener.com
Stock Market Today: S&P 500 Futures Fall, Dow Gains As House Challenges Trump's Military Authority—Broadcom, CrowdStrike, Lululemon In Focus - Sahm
Jade Biosciences prices $150 million public offering at $15 By Investing.com - Investing.com Canada
Jade Biosciences stock falls on public offering announcement By Investing.com - Investing.com South Africa
Jade Biosciences: Jefferies, TD Cowen and UBS Are Joint Book-Running Managers for the Offering >JBIO - Moomoo
Press Release: Jade Biosciences Announces Pricing of Public Offering of Common Stock - Moomoo
Jade Biosciences stock falls on public offering announcement - Investing.com
Jade Biosciences prices $150 million public offering at $15 - Investing.com
Jade Biosciences Plans Public Offering - Moomoo
Jade Biosciences Announces Pricing of Public Offering of Common Stock - The Manila Times
Jade Biosciences Prices Public Offering Of 10 Million Shares at $15 Per Share - TradingView
Biotech Jade Biosciences prices $150M stock sale to fund autoimmune trials - Stock Titan
Jade Biosciences announces proposed public offering By Investing.com - Investing.com India
Jade Biosciences announces proposed public offering - Investing.com
Jade Biosciences Inc Stock (JBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.70%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):